Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828737 | 1.00 | P2RX7 (0.40) | P2RX7CYP2D6MEN1RECQLKMT2A | |
| SCHEMBL828725 | 1.00 | P2RX7 (0.40) | P2RX7CYP2D6MEN1RECQLKMT2A | |
| SCHEMBL829241 | 0.81 | P2RX7 (0.45) | P2RX7OPRL1KCNH2 | |
| SCHEMBL829240 | 0.81 | P2RX7 (0.45) | P2RX7OPRL1KCNH2 | |
| SCHEMBL828464 | 0.81 | P2RX7 (0.45) | P2RX7OPRL1KCNH2 | |
| SCHEMBL829005 | 0.81 | P2RX7 (0.45) | P2RX7OPRL1KCNH2 | |
| SCHEMBL828567 | 0.81 | OPRL1 (0.50) | P2RX7CYP2D6MEN1RECQLKMT2A | |
| SCHEMBL828324 | 0.81 | OPRL1 (0.50) | P2RX7CYP2D6MEN1RECQLKMT2A | |
| SCHEMBL828684 | 0.81 | OPRL1 (0.50) | P2RX7CYP2D6MEN1RECQLKMT2A | |
| SCHEMBL828702 | 0.77 | CALCRL (0.47) | P2RX7OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | P2RX7 182/4885CYP2D6 2744/4885MEN1 2013/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | P2RX7 182/4885CYP2D6 2744/4885MEN1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.